Page 225 - Binder2

2. Opportunity for immune reprogramming,
potentially allowing for long-term tolerance even if
IV forms are used later

In some models, oral enzyme delivery has even been
explored as a primer—a way to teach the immune system
to accept subsequent injected doses without triggering an
ADA response.

That’s not just delivery optimization. That’s tolerogenic
strategy.

What Comes Next

Several startups are now advancing edible enzyme
therapies toward human trials—not just for Gaucher’s, but
for Pompe, phenylketonuria (PKU), and more. As these
platforms mature, we can expect to see:

• Daily or weekly oral dosing replacing biweekly
infusions
• Pediatric formulations designed for easier
compliance
• Combined therapeutic + tolerogenic regimens
• Cost reductions that make treatment viable in
resource-limited settings

This isn’t just a better form of enzyme therapy.
It’s an entirely different architecture—one built for
accessibility, immune harmony, and global scale.

The lesson is clear:
When you stop designing enzymes for industrial delivery—

223